That's why I said "should" and not "will". You can look at the rate of revenue growth and make an educated guess that the lender isn't going to make the terms so restrictive that the company will be unable to access the cash. They are already being compensated for risk via the high rate.
Given prior suspension of guidance I don't think the miss matters much. The stock will likely move down as a knee jerk reaction to the lower than expected numbers, but don't discount the longer-term impact of the move to stop diluting shareholders. That is very rare in a company at TEAR's stage of development where most fall prey to convertible preferred issuances that result in a death spiral of dilution and manipulation.
Guidance or no guidance? The CC Q&Q includes a question about guidance. The answer - we don't want to provide guidance but we really think we can beat this year's 35% growth rate **wink wink**
What's in a name? I'm losing track of the different names these guys are slapping on their sales programs. Its time to execute.
New device? Expectation of a new device by end of 2015 (for use in studies) is interesting but given the long slog to get approval for the first device, CLIA, acceptance by medical community, sales, .... a road we are still on, I don't think there is really any value being attributed to this yet. Maybe there will be in 18 months.